ATA422281A - Verfahren zur herstellung des hydrochloridsalzes des h2-antagonisten n-(2-(((5-(dimethylamino)methyl)-2-furanyl)-methyl)-thio)-|thyl-n1-methy -2-nitro-1,1-aethendiamin - Google Patents

Verfahren zur herstellung des hydrochloridsalzes des h2-antagonisten n-(2-(((5-(dimethylamino)methyl)-2-furanyl)-methyl)-thio)-|thyl-n1-methy -2-nitro-1,1-aethendiamin

Info

Publication number: ATA422281A
Authority: AT; Austria
Prior art keywords: methyl; aethendiamin; thyl; methy; furanyl
Prior art date: 1980-10-01

Application number

AT0422281A

Other languages

English (en)

Other versions

AT389696B (de

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-10-01

Filing date

1981-10-01

Publication date

1989-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10516407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATA422281(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1981-10-01 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

1988-09-12 Priority to AT223188A priority Critical patent/AT407956B/de

1989-05-08 Priority to AT109189A priority patent/AT402069B/de

1989-06-15 Publication of ATA422281A publication Critical patent/ATA422281A/de

1990-01-10 Application granted granted Critical

1990-01-10 Publication of AT389696B publication Critical patent/AT389696B/de

Links

QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 title 1
229940122957 Histamine H2 receptor antagonist Drugs 0.000 title 1
239000003485 histamine H2 receptor antagonist Substances 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Furan Compounds (AREA)

AT0422281A 1980-10-01 1981-10-01 Verfahren zur herstellung des hydrochloridsalzes des h2-antagonisten n-(2-(((5-(dimethylamino)methyl)-2-furanyl)-methyl)-thio)-|thyl-n1-methy -2-nitro-1,1-aethendiamin AT389696B (de)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
AT223188A AT407956B (de)	1980-10-01	1988-09-12	Verfahren zur herstellung eines arzneimittels
AT109189A AT402069B (de)	1980-10-01	1989-05-08	Eine neue kristallform des hydrochloridsalzes des h2-antagonisten n-(2-(((5-(dimethylamino)-methyl)-2-furanyl)-me hyl)-thio)-äthyl-n1-methyl-2-nitro- 1, 1-äthendiamin (ranitidin)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB8031634		1980-10-01

Publications (2)

Publication Number	Publication Date
ATA422281A true ATA422281A (de)	1989-06-15
AT389696B AT389696B (de)	1990-01-10

Family

ID=10516407

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT0422281A AT389696B (de)	1980-10-01	1981-10-01	Verfahren zur herstellung des hydrochloridsalzes des h2-antagonisten n-(2-(((5-(dimethylamino)methyl)-2-furanyl)-methyl)-thio)-\|thyl-n1-methy -2-nitro-1,1-aethendiamin

Country Status (29)

Country	Link
US (2)	US4521431A (de)
JP (1)	JPS5791983A (de)
KR (1)	KR870001431B1 (de)
AT (1)	AT389696B (de)
AU (1)	AU549119B2 (de)
BE (1)	BE890574A (de)
CA (1)	CA1202638A (de)
CH (1)	CH652122A5 (de)
CZ (1)	CZ280885B6 (de)
DE (1)	DE3139134A1 (de)
DK (2)	DK167794B1 (de)
ES (1)	ES8301954A1 (de)
FR (1)	FR2491067A1 (de)
GR (1)	GR72499B (de)
HK (1)	HK97985A (de)
IE (1)	IE51604B1 (de)
IL (1)	IL63968A (de)
IT (1)	IT1143237B (de)
KE (1)	KE3549A (de)
LU (1)	LU83661A1 (de)
MY (1)	MY8500747A (de)
NL (1)	NL8104482A (de)
NZ (1)	NZ198522A (de)
PH (2)	PH19489A (de)
PT (1)	PT73744B (de)
SE (1)	SE453500B (de)
SK (1)	SK277922B6 (de)
ZA (1)	ZA816809B (de)
ZW (1)	ZW24481A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI88157C (fi) *	1983-07-15	1993-04-13	Richter Gedeon Vegyeszet	Foerfarande foer framstaellning av vaetekloriden av 1- 2-/5-dimetylaminometyl-2-(furylmetyltio)-etyl/ -amino-1-metylamino-2-nitroetylen
GB8629781D0 (en) *	1986-12-12	1987-01-21	Glaxo Group Ltd	Pharmaceutical compositions
SE8704436D0 (sv) *	1987-11-13	1987-11-13	Pm Konsult Handelsbolag	Anvendning av antisekretoriska substanser for nya indikationer
IL90245A (en) *	1988-05-11	1994-04-12	Glaxo Group Ltd	Resin adsorbate comprising ranitidine together with a synthetic cation exchange resin, its preparation and pharmaceutical compositions containing it
GB8904182D0 (en) *	1989-02-23	1989-04-05	Glaxo Canada	Pharmaceutical compositions
US5169864A (en) *	1991-11-15	1992-12-08	Baxter International Inc.	Unbuffered premixed ranitidine formulation
CN1048984C (zh) *	1991-12-20	2000-02-02	多坎化学有限公司	晶形1呋喃硝胺氢氯化物的制备
US5338871A (en) *	1991-12-20	1994-08-16	Torcan Chemical Ltd.	Preparation of form 1 ranitidine hydrochloride
KR100296810B1 (ko) *	1993-03-12	2001-10-24	로렌스 티. 마이젠헬더	결정성세프티오퍼유리산
DE4341310A1 (de) *	1993-12-03	1995-06-08	Hexal Pharma Gmbh	Tablette oder Kapsel mit einem Gehalt an stabilem Ranitidinhydrochlorid Form 1
US5407687A (en) *	1994-02-22	1995-04-18	Glaxo Inc.	Ranitidine solid dosage form
EP0754182A1 (de) *	1994-04-08	1997-01-22	Brantford Chemicals Inc.	Form 1 rantidinhydrochlorid mit erhöhter dichte
CA2120874E (en) *	1994-04-08	2002-01-08	Keshava Murthy	Form of form 1 ranitidine
DK0755393T3 (da)	1994-04-15	2001-12-17	Upjohn Co	Nye krystalformer af 1-[5-methansulfonamidoindolyl-2-carbonyl]-4-[3-(1-methylethylamino)-2-pyridinyl]piperazin
IN181699B (de) *	1994-05-13	1998-09-05	Ranbaxy Lab Ltd
IN181698B (de) *	1994-05-13	1998-09-05	Ranbaxy Lab Ltd
NZ272054A (en) *	1994-05-13	1996-05-28	Ranbaxy Lab Ltd	Process for producing form 1 ranitidine hydrochloride
EP1178041A1 (de) *	1994-05-18	2002-02-06	Aventis Pharmaceuticals Inc.	Verfahren zur Herstellung von wasserfreien und Hydrat-Formen von antihistaminischen Piperidinderivaten
US20030045722A1 (en) *	1994-05-18	2003-03-06	Henton Daniel R.	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
EP0694540B1 (de)	1994-06-24	1998-08-19	Ranbaxy Laboratories Limited	Verfahren zur Herstellung von Ranitidinhydrochlorid in der Kristallform 1
MX9703622A (es) *	1994-11-18	1997-08-30	Upjohn Co	Una nueva forma solida fisicamente estable en una fluoroquinolona.
US5538737A (en) *	1994-11-30	1996-07-23	Applied Analytical Industries, Inc.	Oral compositions of H2 -antagonists
US5663381A (en) *	1995-04-21	1997-09-02	Hexal Pharmaceuticals, Inc.	Process for preparing form 1 ranitidine hydrochloride
US5686588A (en) *	1995-08-16	1997-11-11	Yoo; Seo Hong	Amine acid salt compounds and process for the production thereof
AU1972097A (en) *	1996-03-25	1997-10-17	Hoechst Marion Roussel, Inc.	Process for the preparation of form 1 ranitidine hydrochloride
EP0903345B1 (de) *	1997-08-08	2000-10-04	Aventis Pharma Deutschland GmbH	Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
US6287693B1 (en)	1998-02-25	2001-09-11	John Claude Savoir	Stable shaped particles of crystalline organic compounds
IT1317858B1 (it)	2000-02-29	2003-07-15	Pharmexcel S R L	Allomorfo del cloridrato dell'isomero z di derivato dialchilamminofurano, procedimento per la sua produzione e composizione
GB2357762B (en) *	2000-03-13	2002-01-30	Lundbeck & Co As H	Crystalline base of citalopram
US20020183553A1 (en) *	2000-10-19	2002-12-05	Ben-Zion Dolitzky	Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US20060173064A1 (en) *	2001-08-24	2006-08-03	Lippa Arnold S	(-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US6569887B2 (en) *	2001-08-24	2003-05-27	Dov Pharmaceuticals Inc.	(−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US7235655B2 (en) *	2002-03-22	2007-06-26	Pharmacia & Upjohn Company	Processes to prepare eplerenone
AR040661A1 (es) *	2002-07-26	2005-04-13	Theravance Inc	Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
US20080081834A1 (en)	2002-07-31	2008-04-03	Lippa Arnold S	Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US7166641B2 (en) *	2002-10-02	2007-01-23	Yung Shin Pharmaceutical Industrial Co., Ltd.	Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
MXPA05004873A (es) *	2002-11-08	2005-12-05	Dov Pharmaceuticals Inc	Polimorfos de clorhidrato de bicifadina.
TW200510277A (en) *	2003-05-27	2005-03-16	Theravance Inc	Crystalline form of β2-adrenergic receptor agonist
US7384557B2 (en) *	2003-07-14	2008-06-10	Applied Ambient Extraction Process Consultants, Llc	Method and apparatus for removing solute from a solid solute-bearing product
TWI328006B (en) *	2003-12-26	2010-08-01	Nissan Chemical Ind Ltd	Crystal form of quinoline compound and process for its production
US20070043100A1 (en) *	2005-08-16	2007-02-22	Hagen Eric J	Novel polymorphs of azabicyclohexane
US20060100263A1 (en) *	2004-11-05	2006-05-11	Anthony Basile	Antipyretic compositions and methods
US20060100271A1 (en) *	2004-11-08	2006-05-11	Keith Whitehead	Stabilized aqueous ranitidine compositions
EP1915146A4 (de)	2005-07-27	2010-06-02	Dov Pharmaceutical Inc	Neuartige 1-aryl-3-azabicyclo[3.1.0]hexane. herstellung und verwendung zur behandlung von neuropsychiatrischen erkrankungen
DE102005035891A1 (de) *	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20080045725A1 (en)	2006-04-28	2008-02-21	Murry Jerry A	Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
EP2094084A4 (de) *	2006-10-20	2010-01-13	Scinopharm Singapore Pte Ltd	Verfahren zur herstellung von kristallinem wasserfreiem docetaxel
US8138377B2 (en)	2006-11-07	2012-03-20	Dov Pharmaceutical, Inc.	Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
EP2167083B1 (de) *	2007-06-06	2015-10-28	Euthymics Bioscience, Inc.	1- heteroaryl-3-azabicyclo[3.1.0]hexane, verfahren zu ihrer herstellung und ihre verwendung als medikamente
US9133159B2 (en)	2007-06-06	2015-09-15	Neurovance, Inc.	1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
TW201011043A (en) *	2008-06-20	2010-03-16	Chugai Pharmaceutical Co Ltd	Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
CA2837453C (en)	2011-06-30	2017-04-11	Toray Industries, Inc.	Crystals of glycine derivative and pharmaceutical use thereof
US20140206740A1 (en)	2011-07-30	2014-07-24	Neurovance, Inc.	Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
CN106432147B (zh) *	2015-05-26	2018-04-17	烟台市华文欣欣医药科技有限公司	一种制备治疗胃病的药物盐酸雷尼替丁化合物的方法
CN105030694A (zh) *	2015-08-04	2015-11-11	青岛蓝盛洋医药生物科技有限责任公司	一种治疗胃溃疡的药物盐酸雷尼替丁组合物干混悬剂
CN104971053A (zh) *	2015-08-05	2015-10-14	青岛蓝盛洋医药生物科技有限责任公司	一种治疗消化系统疾病的药物盐酸雷尼替丁组合物片剂
CN105055331A (zh) *	2015-08-31	2015-11-18	青岛蓝盛洋医药生物科技有限责任公司	一种治疗消化性溃疡的药物盐酸雷尼替丁组合物颗粒剂
WO2021079183A1 (en) *	2019-10-21	2021-04-29	Sms Pharmaceuticals Limited	Isopropyl alcohol solvent free crystalline ranitidine hydrochloride form-2 which is free of nitrosamine (ndma) impurity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1565966A (en) *	1976-08-04	1980-04-23	Allen & Hanburys Ltd	Aminoalkyl furan derivatives
US4233302A (en) *	1977-12-23	1980-11-11	Glaxo Group Limited	Amine derivatives and pharmaceutical compositions containing them

1981
- 1981-09-28 IL IL63968A patent/IL63968A/xx unknown
- 1981-09-29 PT PT73744A patent/PT73744B/pt unknown
- 1981-10-01 CA CA000387135A patent/CA1202638A/en not_active Expired
- 1981-10-01 PH PH26300A patent/PH19489A/en unknown
- 1981-10-01 SE SE8105812A patent/SE453500B/sv not_active IP Right Cessation
- 1981-10-01 CH CH6322/81A patent/CH652122A5/fr not_active IP Right Cessation
- 1981-10-01 BE BE0/206126A patent/BE890574A/fr not_active IP Right Cessation
- 1981-10-01 IT IT49407/81A patent/IT1143237B/it active
- 1981-10-01 JP JP56154887A patent/JPS5791983A/ja active Granted
- 1981-10-01 ZW ZW244/81A patent/ZW24481A1/xx unknown
- 1981-10-01 DE DE19813139134 patent/DE3139134A1/de active Granted
- 1981-10-01 GR GR66187A patent/GR72499B/el unknown
- 1981-10-01 ES ES505951A patent/ES8301954A1/es not_active Expired
- 1981-10-01 IE IE2287/81A patent/IE51604B1/en not_active IP Right Cessation
- 1981-10-01 NL NL8104482A patent/NL8104482A/nl active Search and Examination
- 1981-10-01 KR KR1019810003689A patent/KR870001431B1/ko not_active Expired
- 1981-10-01 AU AU75955/81A patent/AU549119B2/en not_active Expired
- 1981-10-01 DK DK436281A patent/DK167794B1/da not_active IP Right Cessation
- 1981-10-01 NZ NZ198522A patent/NZ198522A/en unknown
- 1981-10-01 FR FR8118528A patent/FR2491067A1/fr active Granted
- 1981-10-01 ZA ZA816809A patent/ZA816809B/xx unknown
- 1981-10-01 AT AT0422281A patent/AT389696B/de not_active IP Right Cessation
- 1981-10-01 LU LU83661A patent/LU83661A1/fr unknown
1982
- 1982-08-09 US US06/406,710 patent/US4521431A/en not_active Expired - Lifetime
1985
- 1985-03-18 US US06/712,610 patent/US4672133A/en not_active Expired - Lifetime
- 1985-07-17 KE KE3549A patent/KE3549A/xx unknown
- 1985-12-05 HK HK979/85A patent/HK97985A/xx not_active IP Right Cessation
- 1985-12-20 PH PH33229A patent/PH21761A/en unknown
- 1985-12-30 MY MY747/85A patent/MY8500747A/xx unknown
1991
- 1991-12-23 SK SK4035-91A patent/SK277922B6/sk unknown
- 1991-12-23 CZ CS914035A patent/CZ280885B6/cs unknown
1992
- 1992-03-12 DK DK033792A patent/DK167923B1/da not_active IP Right Cessation

Also Published As

Publication number	Publication date
US4672133A (en)	1987-06-09
CH652122A5 (fr)	1985-10-31
SK403591A3 (en)	1995-08-09
SE8105812L (sv)	1982-04-02
ZA816809B (en)	1983-05-25
DK167923B1 (da)	1994-01-03
IL63968A (en)	1985-10-31
NL8104482A (nl)	1982-05-03
ES505951A0 (es)	1983-01-01
DK167794B1 (da)	1993-12-13
KR830007070A (ko)	1983-10-14
CZ280885B6 (cs)	1996-04-17
FR2491067A1 (fr)	1982-04-02
NZ198522A (en)	1985-07-12
PT73744A (en)	1981-10-01
PH21761A (en)	1988-02-18
BE890574A (fr)	1982-04-01
PH19489A (en)	1986-05-14
SK277922B6 (en)	1995-08-09
AT389696B (de)	1990-01-10
DK33792A (da)	1992-03-12
ES8301954A1 (es)	1983-01-01
US4521431A (en)	1985-06-04
IL63968A0 (en)	1981-12-31
AU7595581A (en)	1982-04-08
GR72499B (de)	1983-11-15
IT8149407A0 (it)	1981-10-01
DK33792D0 (da)	1992-03-12
KE3549A (en)	1985-08-16
CZ403591A3 (en)	1994-01-19
DE3139134A1 (de)	1982-05-19
KR870001431B1 (ko)	1987-08-06
IE812287L (en)	1982-04-01
DK436281A (da)	1982-04-02
MY8500747A (en)	1985-12-31
HK97985A (en)	1985-12-13
JPH0443070B2 (de)	1992-07-15
SE453500B (sv)	1988-02-08
PT73744B (en)	1983-10-31
LU83661A1 (fr)	1983-06-08
AU549119B2 (en)	1986-01-16
IT1143237B (it)	1986-10-22
ZW24481A1 (en)	1983-04-27
FR2491067B1 (de)	1984-09-07
IE51604B1 (en)	1987-01-21
DE3139134C2 (de)	1990-04-19
CA1202638A (en)	1986-04-01
JPS5791983A (en)	1982-06-08

Legal Events

Date	Code	Title	Description
2008-02-15	ELA	Expired due to lapse of time

Publication	Publication Date	Title
ATA422281A (de)	1989-06-15	Verfahren zur herstellung des hydrochloridsalzes des h2-antagonisten n-(2-(((5-(dimethylamino)methyl)-2-furanyl)-methyl)-thio)-\|thyl-n1-methy -2-nitro-1,1-aethendiamin
AT382373B (de)	1987-02-25	Verfahren zur herstellung von neuen 2-(4-(4,4dialkyl-2,6-piperidin-dion-1-yl)-butyl)-1piperazinyl)-pyrimidinen
ATA373379A (de)	1981-07-15	Verfahren zur herstellung von neuen 5-substituier-ten hydantoinen
DE59103711D1 (de)	1995-01-12	Verfahren zur herstellung hellfarbiger pasten von alpha-sulfofettsäurealkylester-alkalimetallsalzen.
AT375367B (de)	1984-07-25	Verfahren zur herstellung von als histamin h2-rezeptor-antagonisten wirkenden nitroverbindungen
AT368499B (de)	1982-10-11	Verfahren zur herstellung von neuen 5-substituierten pyranon-verbindungen
DK247181A (da)	1981-12-10	Fremgangsmaade til fremstilling af n-(cykloalkyl)- aminosyreforbindelser
AT358007B (de)	1980-08-11	Verfahren zur herstellung von neuen n-(4-iso- hexylcyclohexylcarbonyl)-aminosaeurederivaten
AT377262B (de)	1985-02-25	Verfahren zur herstellung des neuen 2-(3-(4-
AT363955B (de)	1981-09-10	Verfahren zur herstellung von n-cyano-n'-(2-((4 -methyl-5-imidazolyl)methylthio)aethyl)-n''-alkinylguanidinen
AT358044B (de)	1980-08-11	Verfahren zur herstellung von mefloquin
AT355557B (de)	1980-03-10	Verfahren zur herstellung von neuen alpha-aryl- alpha, alpha-bis(omega- (disubstituiertes amino)alkyl)acetamiden
DE3875447D1 (de)	1992-11-26	Chemisches verfahren zur herstellung von methyl 2-(3-phenoxypyrid-2-yl)-3-propenoaten.
ATA904282A (de)	1985-12-15	Verfahren zur herstellung von salzen von derivaten von n-oxiranmethan-n,n,n-trialkylammonium
AT374475B (de)	1984-04-25	Verfahren zur herstellung von blutdrucksenkendem 6,7-dimethoxy-4-amino-2-(4-(2-furoyl)-1piperazinyl) chinazolinhydrochlorid
ATA225078A (de)	1979-05-15	Verfahren zur herstellung von 2-(2',2',2'- trihalogenaethyl)-4-halogencyclobutan-1-onen
ATA530979A (de)	1981-10-15	Verfahren zur herstellung von 2-(2-hydoxyaethoxy) taethyl-n-(alpha,alpha,alpha-trifluor-m-tolyl) anthranilat
ATA498379A (de)	1981-07-15	Verfahren zur herstellung von n-cyano-n'-methyl-n''-(2-((5-methylimidazol-4-y )-methyl)-thioaethyl) -guanidin
AT383597B (de)	1987-07-27	Verfahren zur herstellung des neuen n-(2-(((5it81081823546/8
AT369365B (de)	1982-12-27	Verfahren zum herstellen von neuen 5-(2-((2,3dihydro-1,4-benzodioxan-2-ylmethyl)-amino)-1hydroxy[thyl)-2-hydroxybenzoes[urederivaten
ATE6502T1 (de)	1984-03-15	Verfahren zur herstellung von n-(1'alkoxycarbonyl[thyl)-2,6-dialkylanilinen.
AT384217B (de)	1987-10-12	Verfahren zur herstellung von 2-(((5-(dimethylamino)methyl-2-furanyl)methyl)thio)aethanamin
DE2967648D1 (en)	1987-04-02	Utilisation of 2-(n-(2,6-dichloro-phenyl)-n-allyl-amino)-imidazoline-(2) for the production of bradycardiac drugs
ATA177783A (de)	1987-12-15	Verfahren zur herstellung von n-(2-(((5-(dimethyl-amino)-methyl-2-furanyl)met yl)thio)aethyl)-n' -methyl-2-nitro-1,1-aethendiamin
ATA483678A (de)	1981-04-15	Verfahren zur herstellung des neuen 3-(4-brom- phenyl)-3-(3-pyridyl)-3-hydroxyprop-1-en und dessen saeureadditionssalzen